Clinical trial
Phase II trial of capecitabine (Xeloda�) + nab-paclitaxel (Abraxane�) in patients with metastatic pancreatic cancer
Objective response rate of Capecitabine + Nab-Paclitaxel as first-line chemotherapy in patients with metastatic pancreatic cancer
| Category | Value |
|---|---|
| Study start date | 2013-06-18 |